Assessments of the unmet need in the management of patients with rheumatoid arthritis: Analyses from the NOR-DMARD registry

Rheumatology (United Kingdom)

Volumn 58, Issue 3, 2019, Pages 481-491

  Olsen, Inge C ^a   Lie, Elisabeth ^a   Vasilescu, Radu ^b   Wallenstein, Gene ^b   Strengholt, Sander ^b   Kvien, Tore K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b PFIZER INC   (United States)

Author keywords

biologic disease modifying antirheumatic drugs; MTX; NOR DMARD; real world data; registry; rheumatoid arthritis

Indexed keywords

ETANERCEPT; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; AGE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL OUTCOME; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SEX; TREATMENT FAILURE; AGED; COMBINATION DRUG THERAPY; DISEASE MANAGEMENT; HEALTH SERVICE; REGISTER; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; REGISTRIES; TREATMENT OUTCOME;

EID: 85062557849     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key338     Document Type: Article

References (39)

1. Smolen JS, Landewe R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
2. Singh JA, Saag KG, Bridges SL Jr et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
3. Fleischmann RM, Huizinga TW, Kavanaugh AF et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2016;2:e000262.
4. Wells AF, Westhovens R, Reed DM et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol 2011;38:2362-8.
5. Soliman MM, Ashcroft DM, Watson KD et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
6. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 2011;50:222-9.
7. Listing J, Strangfeld A, Rau R et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain lowresults from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.
8. Jørgensen TS, Kristensen LE, Christensen R et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology 2015;54:2156-65.
9. Gabay C, Riek M, Scherer A, Finckh A. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology 2015;54:1664-72.
10. Marchesoni A, Zaccara E, Gorla R et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-46.
11. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
12. Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology 2014;53:1664-8.
13. Kim HL, Lee MY, Park SY et al. Comparative effectiveness of cycling of tumor necrosis factor-A (TNF-a) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-A inhibitor using a Bayesian approach. Arch Pharm Res 2014;37:662-70.
14. Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ 2017;20:464-73.
15. Kvien TK, Heiberg LE et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23:S188-94.
16. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
18. Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic diseases. Arthritis Res Ther 2009;11:244.
19. Kaufmann J, Feist E, Roske AE, Schmidt WA. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 2013;32:1347-55.
20. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs-A systematic review and network meta-analysis. Health Qual Life Outcomes 2014;12:102.
21. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
22. Tymms K, Zochling J, Scott J et al. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res (Hoboken) 2014;66:190-6.
23. Alten R, Krüger K, Rellecke J et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence 2016;10:2217-28.
24. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007;56:2135-42.
25. Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 2012;64:2814-23.
26. Zhang J, Shan Y, Reed G et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken) 2011;63:1672-9.
27. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
28. Heiberg T, Kvien TK, Mowinckel P et al. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:967-71.
29. Aletaha D, Stamm T, Kapral T et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944-51.
30. Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther 2017;4:247-61.
31. Taylor PC, Alten R, Gomez-Reino JJ et al. Comparison of biologic disease-modifying anti-rheumatic drug rheumatoid arthritis treatment dynamics across five European Union countries. Rheumatology 2016;55(Suppl 1):i84, abstract 057.
32. Smolen JS, Burmester GR, Combe B et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74.
33. Schiff M, Weinblatt ME, Valente R et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94.
34. Manders SH, Kievit W, Jansen TL et al. Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry. J Rheumatol 2016;43:1787-94.
35. Rintelen B, Zwerina J, Herold M et al. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. BMC Musculoskelet Disord 2016;17:358.
36. Inui K, Koike T. Combination therapy with biologic agents in rheumatic diseases: current and future prospects. Ther Adv Musculoskelet Dis 2016;8:192-202.
37. Reed GW, Gerber RA, Shan Y et al. TNFI and tofacitinib monotherapy and comparative effectiveness in clinical practice: results from CORRONA Registry. Ann Rheum Dis 2017;76(Suppl 2):60, abstract THU0132.
38. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
39. Kanbori M, Suzuka H, Yajima T et al. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2018;28:66-75.